Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon, S Fakharzadeh… - British Journal of …, 2012 - academic.oup.com
Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …
被引用次数：157 相关文章

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon, S Fakharzadeh… - British Journal of …, 2012 - Wiley Online Library
Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

[引用][C] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB KIMBALL, KB GORDON… - British journal of …, 2012 - pascal-francis.inist.fr
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results
from the PHOENIX 1 trial through up to 3 years CNRS Inist Pascal-Francis CNRS Pascal …
[PDF] academia.edu

[PDF][PDF] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

KA Papp - 2012 - academia.edu
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the
PHOENIX 1 trial through up to Page 1 THERAPEUTICS BJD British Journal of Dermatology …

[引用][C] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon, S Fakharzadeh… - British Journal of …, 2012 - cir.nii.ac.jp
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results
from the PHOENIX 1 trial through up to 3 years | CiNii Research CiNii 国立情報学研究所 学術 …

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

AB Kimball, KB Gordon… - British Journal of …, 2012 - search.ebscohost.com
Background An unmet need remains for safe and effective long-term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon, S Fakharzadeh… - British Journal of …, 2012 - infona.pl
Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon… - The British journal …, 2012 - pubmed.ncbi.nlm.nih.gov
Background An unmet need remains for safe and effective long-term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial through up to 3 years

AB Kimball, KB Gordon… - British Journal of …, 2012 - scholars.northwestern.edu
Background An unmet need remains for safe and effective long-term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

AB Kimball, KB Gordon, S Fakharzadeh… - The British Journal of …, 2012 - europepmc.org
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1
trial. Methods Patients (n= 766) with moderate-to-severe psoriasis were randomized to …